Skip to search formSkip to main contentSkip to account menu

Varlitinib Tosylate

Known as: ARRY-543 Ditosilate, 4-N-(3-Chloro-4-(Thiazol-2-Ylmethoxy)Phenyl)-6-N-((4r)-4-Methyl-4,5-Dihydrooxazol-2- Yl)Quinazoline-4,6-Diamine Bis(4-Methylbenzenesulphonate), 4,6-Quinazolinediamine, N(Sup 4)-(3-Chloro-4-(2-Thiazolylmethoxy)Phenyl)-N(Sup 6)-((4r)-4,5-Dihydro-4-Methyl-2-Oxazolyl)-, 4-Methylbenzenesulphonate (1:2) 
The tosylate salt form of varlitinib, an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

5 relations
EGFR protein, humanInhibition of Cell ProliferationReceptor Tyrosine Kinase InhibitionSignal Transduction Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
I^JnLAJr X SYNTHESIS AND CHARACTERIZATION OF FUNTIONALIZED CROWN ETHERS
  • 2015
  • Corpus ID: 56423727
The synthesis and characterization of chromogenic and fluorogenic crown ethers, derived from 4-aza dibenzo 18-crown-6 ether is… 
2011
2011
Procédé pour la préparation de lapatinib et de son sel ditosylate
L'invention porte sur le procede pour la preparation de lapatinib et de sels pharmaceutiquement acceptables de celui-ci par l… 
2001
2001
Quinazoline ditosylate salt compounds
The invention relates to a method for treating the crystallized characteristic disease by at least erbB-based PTK activity using…